Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2025 13:27 ET | Source: Spherix Global Insights

Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights

Exton, Pennsylvania, July 10, 2025 (GLOBE NEWSWIRE) -- Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape...
July 10, 2025 07:35 ET | Source: IGI, Inc.

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
January 31, 2025 13:52 ET | Source: Spherix Global Insights

FDA Approval of Eli Lilly’s Omvoh for Crohn’s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists’ Brand Preferences Among the IL-23 Class, According to Spherix Global Insights

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor available for...
October 31, 2024 08:00 ET | Source: EvolveImmune

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to...
October 01, 2024 10:51 ET | Source: Spherix Global Insights

Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June

EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
September 09, 2024 10:20 ET | Source: Spherix Global Insights

The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market

EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
September 04, 2024 09:00 ET | Source: Bright Mountain Media, Inc.

Bright Mountain Media Appoints Elaine Riddell as Non-Executive Director Bringing 15 Years of Experience Driving Transformative Growth

Boca Raton, FL, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc. (OTCQB: BMTM) ("Bright Mountain" or the "Company"), a global marketing services platform with current investments in...
May 29, 2024 13:46 ET | Source: Lynch Carpenter

Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of 2024, which impacted the personal information...
March 25, 2024 09:10 ET | Source: Professional Diversity Network, Inc.

Professional Diversity Network (PDN) Hosts Successful Virtual Career Fair for Women’s History Month

CHICAGO, March 25, 2024 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ: IPDN) (“PDN” or the “Company”), a developer and operator of online and in-person networks that provide...
March 22, 2024 10:14 ET | Source: Spherix Global Insights

Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market

Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...

Next Page keyboard_arrow_right